| cardiovascular prevention | All results are NS for efficacy inferior to placebo in terms of all cause death in ILLUMINATE, 2007 inferior to placebo in terms of Coronary revascularization in ILLUMINATE, 2007 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| RADIANCE 1, 2007 | vs placebo | | | all cause death 0.00 [0.00; NaN] Cardiovascular death 0.00 [0.00; NaN] Nonfatal stroke 1.01 [0.06; 16.08] Nonfatal myocardial infarction ∞ [NaN; ∞] | | ILLUMINATE, 2007 | vs placebo | | all cause death 1.58 [1.14; 2.18] Coronary revascularization 1.25 [1.10; 1.42] | CHD death 1.21 [0.77; 1.92] coronary events 1.22 [0.98; 1.51] Cardiovascular death 1.40 [0.91; 2.16] Nonfatal myocardial infarction 1.20 [0.94; 1.53] stroke 1.08 [0.70; 1.65] Cardiovascular death, myocardial infarction, stroke 1.16 [0.95; 1.40] | | RADIANCE 2, 2007 | vs placebo | | | | | ILLUSTRATE, 2007 | vs placebo | | | all cause death 1.35 [0.47; 3.86] CHD death 1.01 [0.06; 16.11] Nonfatal myocardial infarction 0.82 [0.40; 1.69] stroke 0.25 [0.05; 1.18] Coronary revascularization 1.21 [0.95; 1.55] |
| Trial | Treatments | Patients | Method |
|---|
| RADIANCE 1, 2007 | atorvastatin combined with 60 mg of torcetrapib (n=450) vs. atorvastatin monotherapy (n=454)
| patients with heterozygous familial hypercholesterolemia
| open Parallel groups Sample size: 450/454 Primary endpoint: carotid intima–media thickness FU duration: 24 months
| | ILLUMINATE, 2007 | torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) (n=7533) vs. atorvastatin alone (n=7534) | patients at highcardiovascular risk | double blind Parallel groups Sample size: 7533/7534 Primary endpoint: MACE FU duration: 1.52y | | RADIANCE 2, 2007 | torcetrapib 60mg daily (on top of atorvastatin attitrated dose) (n=377) vs. placebo +atorvastatin attitrated dose (n=375) | patients with mixed dyslipidaemia | double blind Parallel groups Sample size: 377/375 Primary endpoint: maximum intima-media thickness of 12 carotid segments FU duration: 24 months | | ILLUSTRATE, 2007 | atorvastatin plus 60 mg of torcetrapib daily (n=591) vs. atorvastatin monotherapy (n=597) | patients with coronary disease | open Parallel groups Sample size: 591/597 Primary endpoint: intravascular ultrasonography FU duration: 24 months |
|
| familial hypercholesterolemia | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| RADIANCE 1, 2007 | vs placebo | | | all cause death 0.00 [0.00; NaN] Cardiovascular death 0.00 [0.00; NaN] Nonfatal stroke 1.01 [0.06; 16.08] Nonfatal myocardial infarction ∞ [NaN; ∞] |
| Trial | Treatments | Patients | Method |
|---|
| RADIANCE 1, 2007 | atorvastatin combined with 60 mg of torcetrapib (n=450) vs. atorvastatin monotherapy (n=454)
| patients with heterozygous familial hypercholesterolemia
| open Parallel groups Sample size: 450/454 Primary endpoint: carotid intima–media thickness FU duration: 24 months
|
|
